曲妥珠单抗德鲁替康治疗人表皮生长因子受体2表达的晚期或复发性子宫癌肉瘤(NCCH1615):STATICE试验
该试验纳入既往接受过化疗的复发性子宫癌肉瘤且HER2免疫组化评分≥1+的患者,分HER2高表达组(评分≥2+,22例)和低表达组(评分1+,10例)。曲妥珠单抗德鲁替康每3周静脉给药一次。HER2高表达组中心评估客观缓解率为54.5%(95% CI 32.2-75.6),低表达组为70.0%(95% CI 34.8-93.3)。结论认为曲妥珠单抗德鲁替康对子宫癌肉瘤有疗效,无论HER2状态如何,安全性总体与既往报告一致。
要点
- HER2高表达组中心评估客观缓解率为54.5%(95% CI 32.2-75.6)。
- HER2低表达组中心评估客观缓解率为70.0%(95% CI 34.8-93.3)。
- ≥3级不良事件发生在20例患者(61%),1-2级肺炎/间质性肺病8例(24%),3级1例(3%)。
核心结论
- 曲妥珠单抗德鲁替康对子宫癌肉瘤患者有疗效,无论HER2状态如何;安全性特征与既往报告总体一致,毒性经适当监测和治疗可控。
研究设计与样本
- 该研究为NCCH1615 STATICE试验,纳入既往接受过化疗的复发性子宫癌肉瘤且HER2免疫组化评分≥1+的患者,分为HER2高表达组(免疫组化评分≥2+,n=22)和低表达组(免疫组化评分1+,n=10)分别进行主要和探索性分析。
- 曲妥珠单抗德鲁替康6.4或5.4 mg/kg每3周静脉给药一次,直至不可接受的毒性或疾病进展;剂量调整基于乳腺癌更新后的II期推荐剂量5.4 mg/kg。
- 主要终点为HER2高表达组中心评估的客观缓解率;次要终点包括研究者评估的HER2高表达组总缓解率、HER2低表达组总缓解率、无进展生存期、总生存期和安全性。
主要发现
- HER2高表达组和低表达组中心评估的客观缓解率分别为54.5%(95% CI 32.2-75.6)和70.0%(95% CI 34.8-93.3);研究者评估的客观缓解率分别为68.2%和60.0%。
- HER2高表达组和低表达组的中位无进展生存期分别为6.2个月和13.3个月,中位总生存期分别为6.7个月和未达到。
- ≥3级不良事件发生在20例患者(61%);1-2级和3级肺炎/间质性肺病分别发生在8例(24%)和1例(3%)患者。
关键数值与推荐
- HER2高表达定义为免疫组化评分≥2+,低表达定义为免疫组化评分1+。
- 曲妥珠单抗德鲁替康给药剂量为6.4或5.4 mg/kg,每3周一次;剂量调整基于乳腺癌更新后的II期推荐剂量5.4 mg/kg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) expressing HER2. PATIENTS AND METHODS: Patients with recurrent UCS with HER2 immunohistochemistry scores ≥1+ previously treated with chemotherapy were included. Patients were assigned to the HER2-high (immunohistochemistry score ≥2+; n = 22) or low (immunohistochemistry score of 1+; n = 10) groups for primary and exploratory analyses, respectively. Trastuzumab deruxtecan 6.4 or 5.4 mg/kg was administered intravenously once every 3 weeks until unacceptable toxicity or disease progression. Dose modification was based on the updated recommended phase II dose for breast cancer to be 5.4 mg/kg. The primary end point was the objective response rate by central review in the HER2-high group. Secondary end points included the overall response rate (ORR) in the HER2-high group by investigator assessment, ORR in the HER2-low group, progression-free survival (PFS), overall survival (OS), and safety. RESULTS: The ORR by central review in the HER2-high and HER2-low groups were 54.5% (95% CI, 32.2 to 75.6) and 70.0% (95% CI, 34.8 to 93.3) and those by investigator assessments were 68.2% and 60.0%, respectively. The median PFS and OS in the HER2-high and HER2-low groups were 6.2 and 13.3 months and 6.7 months and not reached, respectively. Grade ≥ 3 adverse events occurred in 20 patients (61%). Grades 1-2 and 3 pneumonitis/interstitial lung disease occurred in eight (24%) and one (3%) patient, respectively. CONCLUSION: Trastuzumab deruxtecan has efficacy in patients with UCS, regardless of HER2 status. The safety profile was generally consistent with that previously reported. Toxicities were manageable with appropriate monitoring and treatment.
引用
- Nishikawa T, Hasegawa K, Matsumoto K, et al. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. J Clin Oncol. 2023. PMID: 36977309. doi:10.1200/JCO.22.02558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。